BioSpace News Archive

RealView Imaging Ltd. announced the completion of its $10M series C financing round.

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, today announced that it will host a virtual Research and Development (R&D) Day for analysts and investors on Wednesday, July 29, 2020 from 12:00pm to 3:00pm ET.

Harvard University’s Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules

CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, announced the commercial launch for the Tiger® MIS X-Tab Pedicle Screw System.

ERC-USA, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, today announced that NYU Winthrop Hospital (NYU) has agreed to treat one of its recurrent, refractory glioblastoma multiforme (GBM) patients with ERC’s lead therapy, ERC1671, under federal and state Right-to-Try laws (RTT).

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 3, 2020 on Wednesday, August 5, 2020 after the market close. STAAR will host a conference call and webcast on Wednesday, August 5, at 4:30 p.m. Eastern / 1:30

Life sciences companies and doctors can leverage Veeva CRM Engage Meeting across the online meeting platforms they’re already using

Vesigen Therapeutics launched today launched today with the objective to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9,

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.

IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per Share $1.18 R&D Solutions quarterly net book-to-bill ratio 1.64x including pass throughs and 1.60x excluding pass throughs; contracted backlog including pass throughs grew 13.5 percent year-over-year to $20.5 billion